Why Is Belite Bio Stock Soaring Friday?
Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
Stocks · News reference
Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Belite Bio shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $303 price target.
This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.